Status:
WITHDRAWN
GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start
Lead Sponsor:
Bayer
Collaborating Sponsors:
Amgen
Conditions:
Carcinoma, Hepatocellular
Eligibility:
All Genders
18+ years
Brief Summary
This study is an international prospective, open-label, multi-center, non-interventional study. The protocol will allow enrollment of all patients with diagnosis of HCC in whom a decision to treat wit...
Eligibility Criteria
Inclusion
- Outpatients with histologically/cytologically documented or radiographically diagnosed HCC in whom a decision to treat with sorafenib has not been made at this time. Radiographic diagnosis needs typical findings of HCC by radiographic method i.e. on multi-dimensional dynamic CT, CT hepatic arteriography (CTHA)/CT arterial portography (CTAP) or MRI.
- Patients must have signed an informed consent form
- Patients must have a life expectancy of at least 8 weeks
Exclusion
- Patients in whom a decision to treat with sorafenib is made at time of study start
- Patients who have received sorafenib in the past or are currently treated with sorafenib
- Hospice patients
Key Trial Info
Start Date :
November 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01191385
Start Date
November 1 2010
End Date
December 1 2013
Last Update
August 16 2017
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Locations, Arkansas, United States
2
Multiple Locations, California, United States
3
Multiple Locations, Colorado, United States
4
Multiple Locations, District of Columbia, United States